Human Genome Sciences, Inc. Lupus Drug, Benlysta May Spur Takeover on Approval

Bloomberg -- Human Genome Sciences Inc. may get U.S. regulatory approval next month for the first new lupus treatment in 50 years, a move that could spur acquisition offers.

MORE ON THIS TOPIC